Galderma Launches Sculptra in China to Boost Aesthetics Market Growth

Swiss firm Galderma has announced the launch of Sculptra, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA) formulation, in China. This follows Sculptra’s approval by China’s National Medical Products Administration for correcting mid-facial volume loss and/or contour deficiencies last year.

Sculptra – which works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance – will now be available in China, where growth of aesthetics has outpaced the global market in the past decade. This launch is indicative of Galderma’s commitment to expanding its unparalleled aesthetics portfolio into new geographies, in order to meet the needs of even more patients and healthcare professionals.

China is a major market for Galderma, where sales have fueled the company’s strong performance across product categories. The aesthetics industry in China has also experienced remarkable growth in recent years, driven by increasing consumer demand for beauty and wellness treatments. 

The market is expected to continue expanding at a rate of up to 15% in the coming years, and research has shown that many Chinese consumers prioritize the safety and outcomes of their aesthetic treatments. Sculptra is well placed to meet these expectations as its extensive safety profile and high satisfaction rate has been demonstrated in more than 10,000 patients in clinical studies over 25 years.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!